{"id":476617,"date":"2020-03-27T19:38:01","date_gmt":"2020-03-27T19:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=476617"},"modified":"2020-03-27T19:38:01","modified_gmt":"2020-03-27T19:38:01","slug":"vitiligo-companies-assessment-report-2020-emerging-drugs-and-competitive-landscape","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/vitiligo-companies-assessment-report-2020-emerging-drugs-and-competitive-landscape_476617.html","title":{"rendered":"Vitiligo Companies Assessment Report, 2020: Emerging drugs and Competitive landscape"},"content":{"rendered":"
\"Vitiligo<\/a><\/div>\n
“Vitiligo Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Vitiligo market. A detailed picture of the Vitiligo pipeline landscape is provided, which includes the disease overview and Vitiligo treatment guidelines.<\/div>\n

“Vitiligo Pipeline Insight, 2020<\/strong><\/a>” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Vitiligo market. A detailed picture of the Vitiligo pipeline landscape is provided, which includes the disease overview and Vitiligo treatment guidelines.<\/p>\n

The assessment part of the report embraces in-depth Vitiligo commercial assessment and clinical assessment of the Vitiligo pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vitiligo collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n

Vitiligo is a condition in which the skin loses melanin, the pigment that determines the color of skin, hair, and eyes. If the cells that do not produce melanin die or no longer produce melanin, slowing growing white patches of irregular shapes appear on the skin. The typical lesions on the skin can be defined as milky white, non-scaly macules that are present with distinct margins.<\/strong><\/p>\n

\"\"<\/p>\n

The therapeutic Vitiligo market in the seven major markets was approximately USD 882.75 million in 2017, which is increasing at a significant Compound Annual Growth Rate (CAGR) during the study period (2017–2028). The United States accounts for the largest Vitiligo market size, in comparison to the other Seven Major Markets, i.e., EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Among the EU5 countries, Germany had the highest market size of Vitiligo, with approximately USD 56.27 million in 2017, while France had the smallest Vitiligo market size with approximately USD 22.43 million in 2017.<\/p>\n

“The female population was found to be more prevalent than the male population.”<\/strong><\/p>\n

View full report: <\/strong>https:\/\/www.delveinsight.com\/sample-request\/vitiligo-pipeline-insight<\/p>\n

Pruritus Analytical Perspective
<\/strong>1. In-depth Pruritus Commercial Assessment of products
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing\/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.<\/p>\n

2. Pruritus Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.<\/p>\n

The key pharma players in Vitiligo market are:<\/strong>
1. Incyte Corporation
2. Clinuvel Pharmaceutical
3. Aclaris Therapeutics
4. Celgene
5. Pfizer<\/p>\n

The launch of the emerging therapies is expected to significantly impact the Vitiligo treatment scenario in the upcoming years:-<\/strong>
Drugs covered:<\/strong>
1. INCB018424
2. SCENESSE (afamelanotide)<\/p>\n

Request for sample pages<\/strong>: https:\/\/www.delveinsight.com\/sample-request\/vitiligo-pipeline-insight<\/p>\n

Table of Contents:<\/strong>
1. Report Introduction
2. Vitiligo
3. Vitiligo  Current Treatment Patterns
4. Vitiligo  – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Vitiligo Late Stage Products (Phase-III)
7. Vitiligo Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Vitiligo Discontinued Products
13. Vitiligo  Product Profiles
14. Vitiligo  Key Companies
15. Vitiligo  Key Products
16. Dormant and Discontinued Products
17. Vitiligo  Unmet Needs
18. Vitiligo  Future Perspectives
19. Vitiligo  Analyst Review 
20. Appendix
21. Report Methodology<\/p>\n

About DelveInsight:
<\/strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Anuj Rawat
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

“Vitiligo Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Vitiligo market. A detailed picture of the Vitiligo pipeline landscape is provided, which includes the disease overview and Vitiligo treatment … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-476617","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/476617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=476617"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/476617\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=476617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=476617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=476617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}